Babesiosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:108B60.0
Who is this for?
Show terms as
3Active trials2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Babesiosis is an infectious disease caused by intraerythrocytic protozoan parasites of the genus Babesia, transmitted primarily through the bite of infected Ixodes ticks (the same ticks that transmit Lyme disease). The most common species affecting humans are Babesia microti in North America and Babesia divergens in Europe. The disease can also be transmitted through contaminated blood transfusions or, rarely, through congenital (transplacental) transmission. Babesiosis primarily affects the hematologic system, as the parasites invade and destroy red blood cells, leading to hemolytic anemia. Key symptoms include fever, chills, sweats, fatigue, malaise, headache, and myalgia, typically appearing one to four weeks after a tick bite. Laboratory findings commonly reveal hemolytic anemia, thrombocytopenia, elevated liver enzymes, and elevated lactate dehydrogenase. Many infected individuals, particularly those who are immunocompetent, may remain asymptomatic or experience only mild illness. However, the disease can be severe and life-threatening in immunocompromised individuals (especially those who are asplenic, elderly, or receiving immunosuppressive therapy), with complications including acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, and splenic rupture. Treatment depends on disease severity. For mild to moderate cases, the standard regimen is a combination of atovaquone and azithromycin for 7 to 10 days. For severe cases, the preferred treatment is intravenous clindamycin combined with oral quinine, along with supportive care including red blood cell exchange transfusion in cases of high parasitemia (typically greater than 10%), severe hemolysis, or organ compromise. Immunocompromised patients may require prolonged courses of antimicrobial therapy. Prevention strategies focus on tick avoidance measures and screening of blood donations in endemic areas.

Clinical phenotype terms— hover any for plain English:

Clinodactyly of the 5th toeHP:0001864
Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Nov 2025B-FREE Chronic Babesiosis Study

60 Degrees Pharmaceuticals LLC — PHASE2

TrialRECRUITING
Nov 2025Human Babesiosis in Metropolitan France

University Hospital, Strasbourg, France

TrialRECRUITING
Jun 2024Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

60 Degrees Pharmaceuticals LLC — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Babesiosis.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 22 trials
B-FREE Chronic Babesiosis Study
Phase 2
Actively Recruiting
· Sites: New York, New York · Age: 1899 yrs
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Phase 2
Actively Recruiting
· Sites: Boston, Massachusetts · Age: 1899 yrs
Other1 trial
Human Babesiosis in Metropolitan France
Actively Recruiting
· Sites: Strasbourg · Age: 1899 yrs

Specialists

2 foundView all specialists →
PM
Philip J Molloy, MD
PLYMOUTH, MA
Specialist
PI on 1 active trial
AM
Alexander PFAFF, MCU-PH
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Babesiosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open BabesiosisForum →

No community posts yet. Be the first to share your experience with Babesiosis.

Start the conversation →

Latest news about Babesiosis

Disease timeline:

New recruiting trial: Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

A new clinical trial is recruiting patients for Babesiosis

New recruiting trial: Human Babesiosis in Metropolitan France

A new clinical trial is recruiting patients for Babesiosis

New recruiting trial: B-FREE Chronic Babesiosis Study

A new clinical trial is recruiting patients for Babesiosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Babesiosis

What is Babesiosis?

Babesiosis is an infectious disease caused by intraerythrocytic protozoan parasites of the genus Babesia, transmitted primarily through the bite of infected Ixodes ticks (the same ticks that transmit Lyme disease). The most common species affecting humans are Babesia microti in North America and Babesia divergens in Europe. The disease can also be transmitted through contaminated blood transfusions or, rarely, through congenital (transplacental) transmission. Babesiosis primarily affects the hematologic system, as the parasites invade and destroy red blood cells, leading to hemolytic anemia.

Are there clinical trials for Babesiosis?

Yes — 3 recruiting clinical trials are currently listed for Babesiosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Babesiosis?

2 specialists and care centers treating Babesiosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.